DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)
China
· Delayed Price · Currency is CNY 19.82
+0.15 (0.76%)
Mar 6, 2026, 3:00 PM CST
SHA:603233 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 26,198 | 25,861 | 23,931 | 20,780 | 16,759 | 14,262 | Upgrade
|
| Other Revenue | 635.56 | 635.56 | 599.94 | 467.67 | - | 320.64 | Upgrade
|
| Revenue | 26,834 | 26,497 | 24,531 | 21,248 | 16,759 | 14,583 | Upgrade
|
| Revenue Growth (YoY) | 1.11% | 8.01% | 15.45% | 26.78% | 14.92% | 30.89% | Upgrade
|
| Cost of Revenue | 17,614 | 17,422 | 15,795 | 13,226 | 10,385 | 8,993 | Upgrade
|
| Gross Profit | 9,220 | 9,074 | 8,736 | 8,022 | 6,374 | 5,590 | Upgrade
|
| Selling, General & Admin | 7,240 | 7,424 | 6,808 | 6,270 | 5,187 | 4,173 | Upgrade
|
| Research & Development | 49.47 | 51.68 | 80.93 | 74.38 | 44.61 | 4.7 | Upgrade
|
| Other Operating Expenses | 68.38 | 35.47 | 35.32 | 64.57 | 29.94 | 44.27 | Upgrade
|
| Operating Expenses | 7,370 | 7,527 | 6,940 | 6,432 | 5,273 | 4,227 | Upgrade
|
| Operating Income | 1,850 | 1,547 | 1,796 | 1,590 | 1,101 | 1,363 | Upgrade
|
| Interest Expense | -222.43 | -248.83 | -239.26 | -231.97 | -212.04 | -11.5 | Upgrade
|
| Interest & Investment Income | 81.13 | 82.23 | 91.75 | 68.89 | 77.7 | 67.69 | Upgrade
|
| Other Non Operating Income (Expenses) | -44.45 | -46.32 | -49.85 | -48.52 | -29.15 | -29.91 | Upgrade
|
| EBT Excluding Unusual Items | 1,665 | 1,335 | 1,599 | 1,379 | 937.76 | 1,389 | Upgrade
|
| Impairment of Goodwill | -38.6 | -38.6 | -6.21 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 20.59 | 10.61 | 4.38 | -18.71 | 34.57 | 2.75 | Upgrade
|
| Gain (Loss) on Sale of Assets | 20.67 | 19.21 | 3.43 | 18.73 | 5.63 | -2.53 | Upgrade
|
| Asset Writedown | 1.44 | - | - | - | - | - | Upgrade
|
| Other Unusual Items | 13.89 | 13.89 | 27.05 | 36.36 | 65.94 | 57.33 | Upgrade
|
| Pretax Income | 1,683 | 1,340 | 1,628 | 1,415 | 1,044 | 1,446 | Upgrade
|
| Income Tax Expense | 457.04 | 359.73 | 397.12 | 335.62 | 239.52 | 363.39 | Upgrade
|
| Earnings From Continuing Operations | 1,226 | 979.94 | 1,231 | 1,079 | 804.39 | 1,083 | Upgrade
|
| Minority Interest in Earnings | -87.87 | -65.19 | -64.16 | -43.55 | -13.16 | -20.84 | Upgrade
|
| Net Income | 1,138 | 914.75 | 1,166 | 1,036 | 791.23 | 1,062 | Upgrade
|
| Net Income to Common | 1,138 | 914.75 | 1,166 | 1,036 | 791.23 | 1,062 | Upgrade
|
| Net Income Growth | 33.80% | -21.58% | 12.63% | 30.90% | -25.51% | 51.17% | Upgrade
|
| Shares Outstanding (Basic) | 1,125 | 1,129 | 1,133 | 1,138 | 1,130 | 1,133 | Upgrade
|
| Shares Outstanding (Diluted) | 1,125 | 1,129 | 1,133 | 1,138 | 1,130 | 1,133 | Upgrade
|
| Shares Change (YoY) | -0.96% | -0.28% | -0.50% | 0.69% | -0.24% | 2.65% | Upgrade
|
| EPS (Basic) | 1.01 | 0.81 | 1.03 | 0.91 | 0.70 | 0.94 | Upgrade
|
| EPS (Diluted) | 1.01 | 0.81 | 1.03 | 0.91 | 0.70 | 0.94 | Upgrade
|
| EPS Growth | 35.09% | -21.36% | 13.19% | 30.00% | -25.33% | 47.27% | Upgrade
|
| Free Cash Flow | 3,922 | 1,630 | 1,377 | 2,722 | 260.05 | 1,162 | Upgrade
|
| Free Cash Flow Per Share | 3.49 | 1.44 | 1.22 | 2.39 | 0.23 | 1.02 | Upgrade
|
| Dividend Per Share | 0.650 | 0.620 | 0.310 | 0.500 | 0.347 | 0.463 | Upgrade
|
| Dividend Growth | 4.84% | 100.00% | -38.00% | 43.97% | -24.99% | 60.04% | Upgrade
|
| Gross Margin | 34.36% | 34.25% | 35.61% | 37.76% | 38.03% | 38.33% | Upgrade
|
| Operating Margin | 6.89% | 5.84% | 7.32% | 7.48% | 6.57% | 9.34% | Upgrade
|
| Profit Margin | 4.24% | 3.45% | 4.75% | 4.87% | 4.72% | 7.28% | Upgrade
|
| Free Cash Flow Margin | 14.62% | 6.15% | 5.61% | 12.81% | 1.55% | 7.96% | Upgrade
|
| EBITDA | 3,536 | 3,131 | 3,244 | 1,808 | 1,306 | 1,533 | Upgrade
|
| EBITDA Margin | 13.18% | 11.82% | 13.22% | 8.51% | 7.79% | 10.51% | Upgrade
|
| D&A For EBITDA | 1,685 | 1,584 | 1,448 | 218.06 | 204.62 | 170.77 | Upgrade
|
| EBIT | 1,850 | 1,547 | 1,796 | 1,590 | 1,101 | 1,363 | Upgrade
|
| EBIT Margin | 6.89% | 5.84% | 7.32% | 7.48% | 6.57% | 9.34% | Upgrade
|
| Effective Tax Rate | 27.16% | 26.85% | 24.40% | 23.72% | 22.94% | 25.12% | Upgrade
|
| Revenue as Reported | 26,834 | 26,497 | 24,531 | 21,248 | 16,759 | 14,583 | Upgrade
|
| Advertising Expenses | - | 25.49 | 30.81 | 26.27 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.